Growing up on a family farm convinced Rick Workman that he didn’t want to be a farmer. He became a dentist instead – and then built the largest dental conglomerate in the nation and made a billion dollars. Read the full story: https://t.co/oatzFRIoac📸: Jamel Toppin for Forbes https://t.co/D7tpZhOF3A ...

Growing up on a family farm convinced Rick Workman that he didn’t want to be a farmer. He became a dentist instead – and then built the largest dental conglomerate in the nation and made a billion dollars. Read the full story: https://t.co/oatzFRIoac📸: Jamel Toppin for Forbes https://t.co/1IaSbe87aR ...

Uber and Rivian Partnership - Uber will invest up to $1.25 billion in Rivian through 2031 as part of a robo taxi partnership [1][2] - Under the agreement, Uber plans to purchase 10,000 fully autonomous R2 robo taxis, with an option for an additional 40,000 in 2030, contingent on regulatory approval and production milestones [2][3] - The goal is to deploy up to 50,000 autonomous vehicles globally, focusing on scaling the R2 platform [3] Market Reaction - Rivian's shares increased by 6.8% following the announcement, indicating investor enthusiasm for the autonomy story [4] - Uber's shares saw a slight increase of about 0.5%, reflecting a positive market sentiment towards both companies [5] Five Below Earnings - Five Below reported strong earnings, with adjusted EPS of $4.31, surpassing the expected $3.99, and revenue of $1.73 billion, also exceeding expectations [7][8] - The company experienced a revenue increase of over 24% year-over-year, with same-store sales up 15%, indicating strong demand among teens and younger consumers [9][10] Align Technology and Activist Investor Activity - Elliot Management has built a significant stake in Align Technology, the maker of Invisalign, leading to a 3.5% increase in shares [12][13] - Despite challenges since the pandemic, Align's shares have shown signs of stabilization and recovery, with improving dental trends noted by Barclays [14][15]

Core Insights - Sonendo, Inc. is on track to achieve breakeven in the second half of 2026, supported by operational improvements and strategic collaborations [1][4]. Financial Performance - The company reported a significant reduction in free cash flow burn to $10.9 million in 2025 from $24.8 million in 2024 [4]. - Loss from operations decreased to $13.5 million in 2025 from $29.4 million in 2024, while adjusted EBITDA loss improved to $10.4 million from $23.0 million in the same period [4]. - Gross margin increased to 41.9% for the full year of 2025, up 460 basis points compared to 2024 [4]. - Total revenue for 2025 was $28.6 million, with approximately 82% ($23.4 million) coming from recurring sales of procedure-related consumables and services [4]. Strategic Developments - On November 17, 2025, Sonendo entered a strategic collaboration with a European-based dental company, gaining exclusive rights to sell high-quality products in North America [1]. - The first product launched under this collaboration is FlowLogic™ endodontic files, expected to compete effectively in the market while being offered at a significant discount to GentleWave customers [2]. Product and Market Position - The GentleWave System is designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth, preserving tooth structure and improving clinical outcomes compared to conventional methods [5]. - Over 1.9 million patients have been treated with the GentleWave System, demonstrating its value to endodontists and patients [3].

Core Insights - Haleon is investing £65 million in a new oral health manufacturing plant in Shanghai to enhance its presence in China's gum health market, which is valued at approximately £860 million [1] - The company aims to expand its gum health brand parodontax to 30 cities in China by the end of 2027, targeting a rising middle class with increasing disposable income [1] - Haleon's investment reflects its long-term commitment to improving the health and wellbeing of Chinese consumers through locally tailored products and enhanced manufacturing capabilities [1] Investment and Expansion - The new manufacturing facility will support the expansion of Haleon's oral care portfolio, including global brands like Sensodyne and parodontax, into tier 2 and tier 3 cities in China [1] - Haleon plans to reach over 250 million people through its distribution strategy, which includes e-commerce platforms and retail pharmacies [1] - The investment is part of a broader strategy to respond quickly to evolving consumer preferences and accelerate innovation in the oral care category [1] Product Development - parodontax is the first clinically proven toothpaste in China targeting the root cause of bleeding gums, with a unique sensory profile adapted for local consumers [1] - Haleon's global R&D team collaborated with local scientists to modify the product's flavor and packaging to better appeal to Chinese consumers [1] - The company is focused on delivering high-quality, science-backed products that align with the growing demand for preventative oral care solutions [1] Strategic Priorities - China is identified as a strategic priority for Haleon, with the company aiming to combine global research expertise with local insights to enhance product offerings [1] - The new facility in Shanghai's Lingang New Area will enable Haleon to build a more agile and efficient supply chain, supporting its ambition to reach one billion more consumers by 2030 [1] - Haleon completed the acquisition of its TSKF joint venture in June 2025, further solidifying its position in China's consumer healthcare market [1]

Core Insights - Henry Schein One has launched the next era of Dentrix Ascend, introducing three new packages aimed at enhancing revenue and growth for dental practices and Dental Service Organizations (DSOs) [1] - The new offerings are built on an integrated platform that combines practice management, clinical workflows, imaging, and revenue cycle management, reflecting a shift from legacy systems to modern cloud platforms [1] Product Innovations - The new packages include advanced features such as Voice Notes, Image Verify, Eligibility Pro, and Digital Forms, which leverage AI to streamline operations and reduce administrative burdens [1] - Voice Notes uses generative AI to convert conversations into structured clinical records, while Image Verify assesses clinical images at capture to prevent claim denials [1] - Eligibility Pro performs real-time benefits checks, completing 191 million checks in 2025, and Digital Forms captures insurance data from images, with 22 million forms completed in 2025 [1] Package Offerings - Dentrix Ascend now offers three structured packages: Ascend Accelerate, Ascend Pro, and Ascend Essentials, each designed to cater to different organizational needs and scalability [1] - Ascend Accelerate is tailored for multi-location organizations, while Ascend Pro is for established practices seeking automation, and Ascend Essentials is aimed at new or smaller practices [1] Support and Implementation - The new era of Dentrix Ascend includes AI-powered support through Claire, providing 24/7 assistance and facilitating smooth migration for practices and DSOs [1] - This support aims to help organizations realize value quickly and manage complexity as they scale [1] Market Position - Dentrix and Dentrix Ascend currently serve over 48,000 practices in the U.S. and 90% of the top 50 DSOs, processing approximately 100 million claims annually [1] - The advancements in Dentrix Ascend strengthen its position as a leading platform for modern dental organizations [1]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue was $106.3 million, an increase of 3% year-over-year, adjusting for Geomagic [32] - For the full year 2025, consolidated revenue was $387 million, a decline of 7% year-over-year when adjusting for the divestiture of Geomagic [36] - Non-GAAP gross margin for the fourth quarter was 31%, up 3% when adjusting for Geomagic, but down 2% when adjusting for both Geomagic and regenerative medicine [36] - Adjusted EBITDA for the fourth quarter was negative $5.3 million, an improvement of $17 million compared to the prior year when adjusting for Geomagic [38] Business Line Data and Key Metrics Changes - Industrial Solutions revenue was $55.8 million, an increase of 15% sequentially, driven by strength in aerospace and defense and higher new printer sales [34] - Healthcare Solutions revenue was $50.5 million, growing 18% sequentially, primarily due to strengthening dental material sales and positive performance in personalized health services [34] Market Data and Key Metrics Changes - Aerospace and defense revenue achieved 16% growth for the full year, with expectations of over 20% growth for 2026 [10] - The healthcare solutions segment became the largest healthcare segment, with over 18,000 personalized planning cases provided in 2025 [20] Company Strategy and Development Direction - The company is focusing on cost reduction while investing in key growth initiatives, particularly in aerospace and defense, personalized health services, and dental markets [5][20] - A major expansion of the U.S. facility in Littleton, Colorado, is underway to increase application development and production capacity [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged global economic and geopolitical challenges but expressed confidence in the company's ability to balance cost reductions with R&D continuity [5] - The company anticipates continued growth in aerospace and defense, driven by increased demand for advanced manufacturing technologies [10][19] Other Important Information - The company completed the divestiture of its Geomagic software business on April 1, 2025, impacting revenue comparisons [31] - The company has maintained a sizable R&D budget for 2026, aligned with product investment priorities [73] Q&A Session Summary Question: How should operating expenses be viewed in Q1 compared to Q4? - Management indicated that Q1 is seasonally higher for spending, with slight increases expected in Q1 and Q2, followed by a drop in Q3 and Q4 [43] Question: What is the current revenue contribution from aerospace and defense? - Aerospace and defense is on track to be the largest industrial segment, with 16% year-over-year growth from 2024 to 2025 [45] Question: What drove the revenue upside in Q4? - The revenue upside was attributed to strong performance in aerospace and defense, healthcare parts, and new printer launches [52] Question: Is there an expectation for gross margin improvement in Q1? - Management anticipates gross margin improvement in Q1, driven by operational cost reductions and better pricing [59] Question: How is R&D spending expected to change going forward? - R&D spending is expected to decrease as the company has completed a significant refresh of its product lines, allowing for better operational management [70][73]

Core Viewpoint - BioSyent Inc. has successfully completed the acquisition of Oral Science Inc., a Canadian distributor of specialized healthcare products for dental hygiene and oral health, for a total purchase price of $25.5 million [1][2]. Group 1: Acquisition Details - The acquisition was executed through a Share Purchase Agreement dated February 8, 2026, and involved a cash payment of $22.5 million, along with the issuance of 234,192 common shares valued at $3.0 million [2]. - The cash component was funded by $16.3 million from BioSyent's liquid cash and a $6.0 million loan from RBC Royal Bank [2]. - Additional cash consideration of $2.0 million was paid at closing, representing excess working capital above the required $6.3 million [2]. - The Sellers are entitled to a contingent cash earn-out payment in 2027 based on Oral Science's performance in 2025 and 2026, as well as contingent royalty payments until 2033, with a maximum value of $6.0 million [2]. Group 2: Company Background - Oral Science, founded in 2003, focuses on improving clinical outcomes in periodontal disease, high-risk caries, dry mouth, and oral lesions through advanced healthcare technologies [5]. - BioSyent is a profitable, growth-oriented specialty healthcare company that acquires, markets, and distributes innovative pharmaceutical and oral health products [6]. - BioSyent operates through its Canadian pharma, international pharma, and oral health business units, supporting healthcare professionals in treating patients [6].

Core Insights - Dentsply Sirona and Burkhart Dental Supply are expanding their partnership to include Dentsply Sirona's full portfolio of dental technology solutions, enhancing access for dental professionals [2][3][4] Company Overview - Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with a history of over a century in the dental industry [8] - Burkhart Dental Supply, founded in 1888, is a family-owned full-service dental distributor with a strong presence across the United States, providing a range of dental supplies and services [5][9] Partnership Details - Effective April 1, 2026, Burkhart Dental Supply will offer Dentsply Sirona's advanced technologies, including the CEREC system, intraoral scanners, and extraoral imaging systems, alongside existing preventive and restorative products [3][4] - The partnership aims to simplify purchasing and provide integrated solutions, enhancing local support for dental practices [4][6] Strategic Focus - Dentsply Sirona is committed to building strategic partnerships that facilitate the adoption of digital solutions in dentistry, integrating devices, software, and workflows [6][7] - The collaboration is positioned to help dental professionals work more efficiently and improve patient care through connected dentistry [7][8]

Core Viewpoint - BioSyent Inc. has announced the acquisition of Oral Science Inc., a Canadian distributor of dental healthcare products, for a total purchase price of $25.5 million, which includes cash and shares, aiming to enhance its revenue and diversify its product portfolio [1][2][11]. Transaction Details - The acquisition involves BioSyent purchasing 100% of Oral Science's shares for $25.5 million, comprising $22.5 million in cash and $3.0 million in BioSyent common shares [2]. - The transaction is expected to close by the end of February 2026, pending customary closing conditions and regulatory approvals [3]. About Oral Science - Oral Science, founded in 2003, specializes in dental products and has a diversified sales model, generating over $30 million in gross revenues and more than $4 million in EBITDA for the trailing twelve months ending September 30, 2025 [4][5]. - Approximately one-third of Oral Science's sales come from proprietary products, while two-thirds are from exclusive distribution agreements [4]. Strategic Fit with BioSyent - The acquisition aligns with BioSyent's business model, enhancing its distribution channels and relationships with dental health professionals [6][8]. - Oral Science generates 54% of its revenue from dental clinics and 46% from consumer purchases, providing a balanced sales approach [7]. Future Operations - Oral Science will operate as a standalone business unit within BioSyent, with its current leadership continuing to manage the company [9]. - BioSyent plans to invest in new pharmaceutical and oral health products to drive growth for both companies [9]. Transaction Financing - The acquisition will be financed through BioSyent's liquid cash and a $6.0 million term loan, with expectations to maintain a strong net cash position post-transaction [10]. Key Transaction Highlights - The acquisition is projected to be accretive, with combined pro forma revenues exceeding $70 million and pro forma EBITDA over $15.75 million for the trailing twelve months ending September 30, 2025 [11][12]. - The purchase price implies a multiple of 6.33 times EBITDA, indicating an attractive rate of return for BioSyent [12]. Strategic Priorities - This acquisition supports BioSyent's goals of profitable growth, diversification, and long-term value creation, enhancing its commercial organization [13][14].